272 related articles for article (PubMed ID: 31140992)
1. Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: a meta-analysis.
Feng F; Chen Y; Li M; Yuan JJ; Chang XN; Dong CM
Chin Med J (Engl); 2019 May; 132(10):1212-1217. PubMed ID: 31140992
[TBL] [Abstract][Full Text] [Related]
2. Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials.
Chang W; Xie JF; Xu JY; Yang Y
BMJ Open; 2018 Mar; 8(3):e019338. PubMed ID: 29602841
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials.
Zangrillo A; Putzu A; Monaco F; Oriani A; Frau G; De Luca M; Di Tomasso N; Bignami E; Lomivorotov V; Likhvantsev V; Landoni G
J Crit Care; 2015 Oct; 30(5):908-13. PubMed ID: 26093802
[TBL] [Abstract][Full Text] [Related]
4. The association between levosimendan and mortality in patients with sepsis or septic shock: a systematic review and meta-analysis.
Ge Z; Gao Y; Lu X; Yu S; Qin M; Gong C; Walline JH; Zhu H; Li Y
Eur J Emerg Med; 2024 Apr; 31(2):90-97. PubMed ID: 38015719
[TBL] [Abstract][Full Text] [Related]
5. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials.
Bhattacharjee S; Soni KD; Maitra S; Baidya DK
J Clin Anesth; 2017 Jun; 39():67-72. PubMed ID: 28494911
[TBL] [Abstract][Full Text] [Related]
6. A Meta-Analysis of the Effects of Levosimendan on Cardiac Function and Outcomes in Patients with Sepsis.
Ma Z; Jin H; Liu F; Wang S; Huang P; Fang X
Altern Ther Health Med; 2023 Nov; 29(8):668-673. PubMed ID: 37678873
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction: a systematic review and meta-analysis.
Liu DH; Ning YL; Lei YY; Chen J; Liu YY; Lin XF; Yang ZQ; Xian SX; Chen WT
Sci Rep; 2021 Oct; 11(1):20333. PubMed ID: 34645892
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.
Antcliffe DB; Santhakumaran S; Orme RML; Ward JK; Al-Beidh F; O'Dea K; Perkins GD; Singer M; McAuley DF; Mason AJ; Cross M; Ashby D; Gordon AC
Intensive Care Med; 2019 Oct; 45(10):1392-1400. PubMed ID: 31428804
[TBL] [Abstract][Full Text] [Related]
9. The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials.
Belletti A; Benedetto U; Biondi-Zoccai G; Leggieri C; Silvani P; Angelini GD; Zangrillo A; Landoni G
J Crit Care; 2017 Feb; 37():91-98. PubMed ID: 27660923
[TBL] [Abstract][Full Text] [Related]
10. Effects of levosimendan on mortality in patients with septic shock: systematic review with meta-analysis and trial sequential analysis.
Wang B; Chen R; Guo X; Zhang W; Hu J; Gong Y; Cheng B
Oncotarget; 2017 Nov; 8(59):100524-100532. PubMed ID: 29245998
[TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of the Efficacy of Levosimendan in the Treatment of Severe Sepsis Complicated with Septic Cardiomyopathy.
Guan Q; Zhang C; Li B; Huang D; Li A; Qin J; Zhang X
Heart Surg Forum; 2023 Oct; 26(5):E609-E620. PubMed ID: 37920078
[TBL] [Abstract][Full Text] [Related]
12. Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta-analysis.
Ni YN; Liu YM; Wang YW; Liang BM; Liang ZA
Am J Emerg Med; 2019 Sep; 37(9):1657-1664. PubMed ID: 30522935
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials.
Santhakumaran S; Gordon A; Prevost AT; O'Kane C; McAuley DF; Shankar-Hari M
Crit Care; 2019 May; 23(1):156. PubMed ID: 31053084
[TBL] [Abstract][Full Text] [Related]
14. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis.
Fujii T; Ganeko R; Kataoka Y; Furukawa TA; Featherstone R; Doi K; Vincent JL; Pasero D; Robert R; Ronco C; Bagshaw SM
Intensive Care Med; 2018 Feb; 44(2):167-178. PubMed ID: 29204670
[TBL] [Abstract][Full Text] [Related]
15. [Effects of levosimendan on hemodynamics and cardiac function in patients with septic shock].
Fang M; Dong S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Oct; 26(10):692-6. PubMed ID: 25315937
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan in patients with cardiogenic shock complicating myocardial infarction: A meta-analysis.
Fang M; Cao H; Wang Z
Med Intensiva (Engl Ed); 2018 Oct; 42(7):409-415. PubMed ID: 29126662
[TBL] [Abstract][Full Text] [Related]
17. Human recombinant activated protein C for severe sepsis.
Martí-Carvajal AJ; Solà I; Lathyris D; Cardona AF
Cochrane Database Syst Rev; 2012 Mar; (3):CD004388. PubMed ID: 22419295
[TBL] [Abstract][Full Text] [Related]
18. Early goal-directed therapy in the management of severe sepsis or septic shock in adults: a meta-analysis of randomized controlled trials.
Zhang L; Zhu G; Han L; Fu P
BMC Med; 2015 Apr; 13():71. PubMed ID: 25885654
[TBL] [Abstract][Full Text] [Related]
19. Impact on Efficacy and Safety of Hydrocortisone in Sepsis and Septic Shock - A Systematic Literature Review and Meta-analysis.
Aletreby WT; Alharthy AM; Madi AF; Soliman IR; Hamido HM; Ramadan OE; Alzayer W; Huwait BM; Alodat MA; Mumtaz SA; Mahmood NN; Al Kurdi MH; Farrag HA; Karakitsos D
Arch Iran Med; 2019 Jul; 22(7):394-402. PubMed ID: 31679383
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin for treating sepsis and septic shock.
Alejandria MM; Lansang MA; Dans LF; Mantaring JB
Cochrane Database Syst Rev; 2002; (1):CD001090. PubMed ID: 11869591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
